or Try an Advanced Search...

    Technical Analysis for NVCR - NovoCure Limited

    Grade Last Price % Change Price Change
    F 12.64 3.31% 0.41
    NVCR closed up 3.31 percent on Friday, April 26, 2024, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    Earnings due: May 2
    *** please verify all earnings dates ***
    4 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical NVCR trend table...
    Date Alert Name Type % Chg
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Wide Bands Range Expansion 3.31%
    Oversold Stochastic Weakness 3.31%
    NR7 Range Contraction 2.39%
    Narrow Range Bar Range Contraction 2.39%
    Inside Day Range Contraction 2.39%
    Wide Bands Range Expansion 2.39%
    Oversold Stochastic Weakness 2.39%
    Slingshot Bearish Bearish Swing Setup 4.81%
    Older End-of-Day Signals for NVCR ...

       Recent Intraday Alerts

    Alert Time
    Up 3% about 17 hours ago
    60 Minute Opening Range Breakout about 20 hours ago
    Up 2% about 20 hours ago
    Rose Above Previous Day's High about 21 hours ago
    Rose Above 10 DMA about 21 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    NVCR Chart by TradingView
    Basic chart:

    Profile

    NovoCure Limited develops and commercializes treatment for solid tumor cancers therapy called the tumor treating fields (TTFields). The company markets its proprietary therapy, TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer. NovoCure Limited also conducts clinical trials for the use of TTFields in brain metastases, advanced non-small cell lung cancer, pancreatic cancer, ovarian cancer, and mesothelioma. The company markets its products in the United States, as well as in European Union member states, Switzerland, and Japan. NovoCure Limited was founded in 2000 and is based in Saint Helier, Channel Islands.
    Classification
    Sector: Healthcare
    Industry: Medical Instruments & Supplies
    Keywords: Medicine Cancer Clinical Medicine Oncology Tumor Non Small Cell Lung Cancer Ovarian Cancer Pancreatic Cancer Blastoma Small Cell Lung Cancer Glioblastoma Brain Tumor Solid Tumor Cancers Aging Associated Diseases Metastases Brain Cancer Mesothelioma

    Is NVCR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 25 NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
    Apr 24 Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
    Apr 5 Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
    Apr 1 NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
    Apr 1 Novocure to Report First Quarter 2024 Financial Results
    Mar 30 Why NovoCure Stock Soared 18.3% This Week
    Mar 28 Why Novocure Stock Is Jumping Today
    Mar 28 NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
    Mar 28 NovoCure: Sell The METIS-Inspired Rally
    Mar 27 Peeling Back The Layers: Exploring NovoCure Through Analyst Insights
    See more NVCR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 83.6
    52 Week Low 10.87
    Average Volume 1,338,892
    200-Day Moving Average 17.67
    50-Day Moving Average 14.43
    20-Day Moving Average 13.31
    10-Day Moving Average 12.25
    Average True Range 0.73
    RSI (14) 42.86
    ADX 15.76
    +DI 19.70
    -DI 23.99
    Chandelier Exit (Long, 3 ATRs) 13.86
    Chandelier Exit (Short, 3 ATRs) 13.89
    Upper Bollinger Bands 15.59
    Lower Bollinger Band 11.03
    Percent B (%b) 0.35
    BandWidth 34.28
    MACD Line -0.64
    MACD Signal Line -0.60
    MACD Histogram -0.0383
    Fundamentals Value
    Market Cap 1.35 Billion
    Num Shares 107 Million
    EPS -1.86
    Price-to-Earnings (P/E) Ratio -6.79
    Price-to-Sales 3.35
    Price-to-Book 4.16
    PEG Ratio -0.47
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 13.60
    Resistance 3 (R3) 13.49 13.07 13.44
    Resistance 2 (R2) 13.07 12.83 13.12 13.38
    Resistance 1 (R1) 12.85 12.68 12.96 12.96 13.33
    Pivot Point 12.43 12.43 12.49 12.48 12.43
    Support 1 (S1) 12.21 12.19 12.32 12.32 11.94
    Support 2 (S2) 11.79 12.04 11.84 11.89
    Support 3 (S3) 11.57 11.79 11.84
    Support 4 (S4) 11.68